期刊
NATURE BIOTECHNOLOGY
卷 29, 期 11, 页码 1011-U82出版社
NATURE PORTFOLIO
DOI: 10.1038/nbt.2005
关键词
-
资金
- VistaGen Therapeutics (San Francisco)
- Canadian Institute of Health Research (CIHR) [MOP-84524, MOP-106538]
- Ontario's Ministry of Research and Innovation (MRI) [GL2-CBD3P3]
- Swiss National Foundation
- Heart and Stroke Foundation of Ontario [T6281, NS6636]
- Australian Stem Cell Centre, the National Health and Medical Research Council (NHMRC, Australia)
- National Heart Foundation (Australia)
To identify cell-surface markers specific to human cardiomyocytes, we screened cardiovascular cell populations derived from human embryonic stem cells (hESCs) against a panel of 370 known CD antibodies. This screen identified the signal-regulatory protein alpha (SIRPA) as a marker expressed specifically on cardiomyocytes derived from hESCs and human induced pluripotent stem cells (hiPSCs), and PECAM, THY1, PDGFRB and ITGA1 as markers of the nonmyocyte population. Cell sorting with an antibody against SIRPA allowed for the enrichment of cardiac precursors and cardiomyocytes from hESC/hiPSC differentiation cultures, yielding populations of up to 98% cardiac troponin T-positive cells. When plated in culture, SIRPA-positive cells were contracting and could be maintained over extended periods of time. These findings provide a simple method for isolating populations of cardiomyocytes from human pluripotent stem cell cultures, and thereby establish a readily adaptable technology for generating large numbers of enriched cardiomyocytes for therapeutic applications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据